PMID- 28994141
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20211204
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 33
IP  - 5
DP  - 2018 May
TI  - Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir +/- 
      DASABUVIR +/- ribavirin in clinical practice.
PG  - 1100-1107
LID - 10.1111/jgh.14014 [doi]
AB  - BACKGROUND & AIMS: Drug-drug interactions (DDIs) with 
      ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without 
      ribavirin (OBV/PTV/r +/- DSV +/- RBV) are common in clinical trials. Our aim was to 
      analyze the prevalence and management of potential DDIs and adverse events (AEs) 
      related to DDIs in patients with chronic hepatitis C (CHC) receiving 
      OBV/PTV/r +/- DSV +/- RBV in clinical practice. METHODS: 177 CHC patients started 
      OBV/PTV/r +/- DSV +/- RBV in 4 Spanish hospitals and were screened for potential DDIs 
      using the University of Liverpool database. Patients were classified according to 
      the most serious potential DDIs at baseline and AEs during therapy. RESULTS: At 
      least one potential DDI was found in 110 (62.1%) patients: 100 (56.5%) had at 
      least one manageable potential DDI and 10 (5.6%) at least one contraindicated. 
      Patients with potential DDIs were receiving a higher number of concomitant drugs 
      (4 vs. 2, P < 0.001). Routine medication was modified at baseline due to 
      potential DDIs in 49 (27.7%) patients. During antiviral treatment, 67 (37.9%) 
      patients presented at least one AE. In 9 (4.5%) patients, a DDI was suspected 
      between OBV/PTV/r +/- DSV +/- RBV and the concomitant drug, requiring antiviral 
      discontinuation in 4 patients. CONCLUSIONS: Potential DDIs are frequent with 
      OBV/PTV/r +/- DSV +/- RBV, although a change in baseline medication is made in only 
      one-quarter of patients. More than half of potential DDIs were only followed, and 
      only 5% of patients developed AEs in which the implication of DDIs could not be 
      excluded.
CI  - (c) 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Gonzalez-Colominas, Elena
AU  - Gonzalez-Colominas E
AD  - Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.
FAU - Londono, Maria-Carlota
AU  - Londono MC
AD  - Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
FAU - Morillas, Rosa M
AU  - Morillas RM
AD  - Department of Hepatology, Hospital Germans Trias i Pujol, CIBERehd, Badalona, 
      Spain.
FAU - Torras, Xavier
AU  - Torras X
AD  - Department of Gastroenterology, Hospital Santa Creu i Sant Pau, CIBERehd, 
      Barcelona, Spain.
FAU - Mojal, Sergi
AU  - Mojal S
AD  - Biomedical Research Methods Consultant, Hospital del Mar Medical Research 
      Institute (IMIM), Barcelona, Spain.
FAU - Lens, Sabela
AU  - Lens S
AD  - Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
FAU - Lopez, Dulce
AU  - Lopez D
AD  - Department of Hepatology, Hospital Germans Trias i Pujol, CIBERehd, Badalona, 
      Spain.
FAU - Gallego, Adolfo
AU  - Gallego A
AD  - Department of Gastroenterology, Hospital Santa Creu i Sant Pau, CIBERehd, 
      Barcelona, Spain.
FAU - Marino, Zoe
AU  - Marino Z
AD  - Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
FAU - Ardevol, Merce
AU  - Ardevol M
AD  - Pharmacy Department, Hospital Germans Trias i Pujol, Badalona, Spain.
FAU - Pages, Neus
AU  - Pages N
AD  - Pharmacy Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Sola, Ricard
AU  - Sola R
AD  - Liver Section, Gastroenterology Department, Hospital del Mar, Universitat 
      Autonoma de Barcelona, IMIM, Barcelona, Spain.
FAU - Carrion, Jose A
AU  - Carrion JA
AUID- ORCID: 0000-0001-7191-6081
AD  - Liver Section, Gastroenterology Department, Hospital del Mar, Universitat 
      Autonoma de Barcelona, IMIM, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20180212
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anilides)
RN  - 0 (Carbamates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Macrocyclic Compounds)
RN  - 0 (Sulfonamides)
RN  - 2302768XJ8 (ombitasvir)
RN  - 49717AWG6K (Ribavirin)
RN  - 56HH86ZVCT (Uracil)
RN  - 9DLQ4CIU6V (Proline)
RN  - CKR7XL41N4 (2-Naphthylamine)
RN  - DE54EQW8T1 (dasabuvir)
RN  - HG18B9YRS7 (Valine)
RN  - O3J8G9O825 (Ritonavir)
RN  - OU2YM37K86 (paritaprevir)
SB  - IM
MH  - 2-Naphthylamine
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anilides/administration & dosage/*adverse effects
MH  - Carbamates/administration & dosage/*adverse effects
MH  - Cyclopropanes
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Lactams, Macrocyclic
MH  - Macrocyclic Compounds/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Proline/analogs & derivatives
MH  - Ribavirin/administration & dosage/*adverse effects
MH  - Ritonavir/administration & dosage/*adverse effects
MH  - Sulfonamides/administration & dosage/*adverse effects
MH  - Uracil/administration & dosage/adverse effects/*analogs & derivatives
MH  - Valine
OTO - NOTNLM
OT  - Dasabuvir
OT  - Drug-drug interactions
OT  - Hepatitis C virus
OT  - Ombitasvir
OT  - Paritaprevir
OT  - Ritonavir
EDAT- 2017/10/11 06:00
MHDA- 2018/08/11 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/06/08 00:00 [received]
PHST- 2017/09/26 00:00 [revised]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2017/10/11 06:00 [entrez]
AID - 10.1111/jgh.14014 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2018 May;33(5):1100-1107. doi: 10.1111/jgh.14014. Epub 
      2018 Feb 12.